|
|
 |
|
Viewing report
|
|
|
|
Genzyme Corporation
Datamonitor, May 2011, Pages: 95
This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Genzyme's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Genzyme over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
- Assess the impact of the Allston Landing contamination issues to the company's top line sales performance
- Understand the level of sales growth and portfolio diversification Genzyme will offer Sanofi-Aventis, post acquisition
|
|
|
|
